David Peereboom, MD
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center · Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Peereboom, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:30 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07003542 · A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 GliomasCase Comprehensive Cancer Center · recruiting · Glioblastoma, Brain Tumor · principal investigator
- Ph2NCT05607407 · Methimazole in Patients With Progressive GlioblastomaCase Comprehensive Cancer Center · suspended · Glioblastoma, Glioma · principal investigator
- Ph2NCT04051606 · Regorafenib in Bevacizumab Refractory Recurrent GlioblastomaCase Comprehensive Cancer Center · completed · Recurrent Glioblastoma · principal investigator
- Ph2NCT04013672 · Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First RecurrenceDavid Peereboom · completed · Recurrent Glioblastoma · principal investigator
- Ph1NCT03535350 · Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed GlioblastomaCase Comprehensive Cancer Center · completed · Glioblastoma · principal investigator
- Ph1NCT03514069 · Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and GlioblastomaCase Comprehensive Cancer Center · completed · Glioma, Glioblastoma · principal investigator
- Ph2NCT03452579 · Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBMDavid Peereboom · active not recruiting · Glioblastoma · principal investigator
- Ph1NCT02669173 · Capecitabine + Bevacizumab in Patients With Recurrent GlioblastomaCase Comprehensive Cancer Center · completed · Glioblastoma · principal investigator
- Ph2NCT01894061 · NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent GlioblastomaCase Comprehensive Cancer Center · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph2NCT01095094 · Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade GliomaCase Comprehensive Cancer Center · terminated · Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma · principal investigator
- Ph2NCT00445588 · Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeNational Cancer Institute (NCI) · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph1/Ph2NCT00045708 · A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade GliomasNational Cancer Institute (NCI) · completed · Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NABTT-Consortium Therapeutic Studies of CNS MalignanciesU01CA062475 · NCI · JOHNS HOPKINS UNIVERSITY · PI STUART A GROSSMAN · fiscal years 1994 to 2008Named on NCT00445588, NCT00045708
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in glioblastoma.